TIDMYGEN

RNS Number : 1147T

Yourgene Health PLC

12 November 2019

Yourgene Health plc

("Yourgene" or the "Group" or the "Company")

Notice of Results

Manchester, UK 12 November 2019: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces it will issue its half year results for the six months ending 30 September 2019 on Monday, 2 December 2019.

The Company will host a briefing for private investors that week with Lyn Rees, CEO, and Barry Hextall, CFO, providing a presentation on the results and a business update.

If you would like to register for the briefing, please contact Walbrook PR on 020 7933 8780 or email yourgene@walbrookpr.com.

 
Yourgene Health plc                                                   Tel: +44 (0)161 667 1053 
 Lyn Rees, Chief Executive Officer                               investors@yourgene-health.com 
 Barry Hextall, Chief Financial Officer 
 Joanne Cross, Director of Marketing 
 
Stifel Nicolaus Europe Limited (Sole                                  Tel: +44 (0)20 7710 7600 
 Corporate Broker) 
 Nicholas Moore / Matthew Blawat / Ben 
 Maddison 
Cairn Financial Advisers LLP (NOMAD)                                  Tel: +44 (0)20 7213 0880 
 Liam Murray / James Caithie / Ludovico 
 Lazzaretti 
Walbrook PR Ltd (Media and Investor        Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com 
 Relations)                                              Mob: 07980 541 893 Mob: 07584 391 303 
 Paul McManus / Lianne Cawthorne

About Yourgene Health

Yourgene Health is an international molecular diagnostics group which develops and commercialises genetic products and services. The group works in partnership with global leaders in DNA technology to advance diagnostic science.

Yourgene develops and commercialises simple and accurate molecular diagnostic solutions, primarily for reproductive health. The Group's products include non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, male infertility tests and genetic disease tests. Yourgene's commercial footprint is already established in the UK, Europe, the Middle East, Africa and Asia.

Our product development, research service and commercial capabilities extend across the lifecycle of genetic test development including regulatory submissions. Through our technical expertise and partnerships, Yourgene Health is also extending its genetic testing offering into oncology.

Yourgene Health is headquartered in Manchester, UK with offices in Taipei and Singapore, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". For more information, visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NORBGBDBGBBBGCD

(END) Dow Jones Newswires

November 12, 2019 05:12 ET (10:12 GMT)

Yourgene Health (LSE:YGEN)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024 Haga Click aquí para más Gráficas Yourgene Health.
Yourgene Health (LSE:YGEN)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024 Haga Click aquí para más Gráficas Yourgene Health.